 BOSTON, Oct. 01, 2021 GLOBE NEWSWIRE -- Paratek Pharmaceuticals, Inc. Nasdaq: PRTK, a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases and other public health threats for civilian, government and military use, today announced that on September 30, 2021, the Company granted stock options to five new employees of the Company. These awards were granted pursuant to the Paratek Pharmaceuticals, Inc. 2017 Inducement Plan, as amended, which was approved by the Companys board of directors on June 15, 2017, under Rule 5635c4 of the NASDAQ Listing Rules, for equity grants to employees entering into employment or returning to employment after a bona fide period of non-employment with the Company, as an inducement material to such individuals entering into employment with the Company. The stock options are to acquire, in the aggregate, 9,700 shares of the Companys common stock at a per share exercise price of 4.86, the closing sales price on September 30, 2021, and shall vest over a four-year vesting period, under which 25 of the shares will vest after 12 months of employment, with the remaining shares vesting monthly thereafter over the remaining 36-month period, subject to the employees continuous service. The restricted stock units are to acquire, in the aggregate, 9,600 shares of the Companys common stock and shall vest upon the conclusion of a 36-month vesting period, under which one hundred percent 100 of the restricted stock units will vest after 36 months of employment, subject to the employees continuous service. The stock options and restricted stock units are subject to the terms and conditions of the Paratek Pharmaceuticals, Inc. 2017 Inducement Plan, as amended, and the terms and conditions of the stock option agreement and restricted stock unit award agreement covering each grant. 